

VALEANT PHARMACEUTICALS INTERNATIONAL
Form 8-K
August 02, 2010

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

**FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported):

August 2, 2010

**Valeant Pharmaceuticals International
(Exact Name of Registrant as Specified in Charter)**

Delaware

(State or Other Jurisdiction of Incorporation)

1-11397

(Commission File Number)

33-0628076

(IRS Employer Identification No.)

One Enterprise

Alisa Viejo, California 92656

(Address of Principal Executive Offices)

Registrant's telephone number, including area code:

(949) 461-6000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02 Results of Operations and Financial Condition.

On August 2, 2010, Valeant issued a press release announcing results of operations for the quarter ended June 30, 2010 and certain other financial information as of and for the quarter ended June 30, 2010. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference.

The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release dated August 2, 2010.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Valeant Pharmaceuticals International

Date: August 2, 2010

By: /s/ Peter J. Blott
Peter J. Blott
Executive Vice President and Chief Financial
Officer

INDEX TO EXHIBITS

99.1 Press Release dated August 2, 2010.